Clinical Trials
376 trialsBGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
ELEGANT
Stemline Therapeutics, Inc.
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
TAILORx
National Cancer Institute (NCI)
CAMERAN
UNC Lineberger Comprehensive Cancer Center
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
PIKALO-1
Eli Lilly and Company
ELEGANCE
Novartis
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
FourLight-3
Pfizer
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
University of Illinois at Chicago
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
OPERA-02
Olema Pharmaceuticals, Inc.
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Adjuvant WIDER
Novartis
CAMBRIA-1
AstraZeneca
POWER II
University of Virginia
I-SPY
QuantumLeap Healthcare Collaborative
GIM10-CONSENT
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Novartis
IMPULSE
Novartis
INAVO123
Hoffmann-La Roche
DEBRA
NRG Oncology
SERENA-6
AstraZeneca
PIKASSO-01
Eli Lilly and Company
Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
University of Maryland, Baltimore
PHACS
Institut Claudius Regaud
OXYTAM
Institut Claudius Regaud
MIRHO
Institut Claudius Regaud
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
Providence Health & Services
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
ADEPT
Dana-Farber Cancer Institute
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
EMBER-4
Eli Lilly and Company
SIE-3
Rovi Pharmaceuticals Laboratories
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Hebei Medical University Fourth Hospital
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Novartis
Letrozole After Tamoxifen in Treating Women With Breast Cancer
Canadian Cancer Trials Group
MNEMOSYNE
Centre Oscar Lambret
NeoMARS
Peking University
Morpheus-panBC
Hoffmann-La Roche
OPERA-01
Olema Pharmaceuticals, Inc.
CARABELA
Spanish Breast Cancer Research Group
FELINE
University of Kansas Medical Center